Evgen Pharma PLC Notice of Half Year Results (3472I)
02 Diciembre 2022 - 1:00AM
UK Regulatory
TIDMEVG
RNS Number : 3472I
Evgen Pharma PLC
02 December 2022
Evgen Pharma plc
("Evgen" or "the Company" or "the Group")
Notice of Half Year Results
2 December 2022 - Evgen Pharma plc (AIM: EVG), the clinical
stage drug development company developing sulforaphane-based
medicines for the treatment of multiple diseases, will report its
half year results for the six months ended 30 September 2022 on
Thursday, 8 December 2022.
Dr Huw Jones, Chief Executive Officer, and Richard Moulson,
Chief Financial Officer, will present the results via the Investor
Meet Company platform on 8 December at 14:00 GMT. The presentation
is open to all existing and potential shareholders. Questions can
be submitted pre-event via the Investor Meet Company dashboard up
until 9am the day before the meeting or at any time during the live
presentation.
Investors can sign up to Investor Meet Company for free and add
to meet Evgen Pharma plc here . Investors who already follow Evgen
on the Investor Meet Company platform will automatically be
invited. The presentation and recording will be available on the
Company's website after the event here .
-Ends-
Enquiries:
E vgen P harma plc
Dr Huw Jones, CEO
Richard Moulson, CFO +44 1625 466591
FinnCap (Nominated Advisor and
Broker)
Geoff Nash / Teddy Whiley (Corporate
Finance)
Alice Lane/ Nigel Birks (ECM) +44 20 7220 0500
Instinctif Partners +44 207 457 2020
Melanie Toyne-Sewell / Rozi Morris Evgen@Instinctif.com
/ Agnes Stephens / Adam Loudon
Notes to Editors
About Evgen Pharma plc
Evgen Pharma is a clinical stage drug development company
developing sulforaphane based medicines for the treatment of
multiple diseases. The Company's core technology is Sulforadex(R),
a method for synthesising and stabilising the naturally occurring
compound sulforaphane and novel proprietary analogues based on
sulforaphane.
The Company's lead asset, SFX-01, is a patented composition of
synthetic sulforaphane and alpha-cyclodextrin and has undergone
clinical trials for oestrogen-positive (ER+) metastatic breast
cancer. In September 2021 the FDA granted Orphan Drug status to
SFX-01 in malignant glioma.
The Company also has a wide number of collaborations with
leading academic centres in the UK, Europe and AsiaPac as part of
the continuing strategy to build the data set of safety and
efficacy around the compound. With respect to non-core area, Evgen
signed an out-licensing deal with JuvLife, the dietary products and
functional foods division of Juvenescence Ltd, for the development
of a naturally-sourced sulforaphane nutritional health supplement,
stabilised using Evgen's Sulforadex(R) technology. Evgen also has a
licensing deal with STALICLA SA in neurodevelopmental disorders and
schizophrenia.
The Company has its headquarters and registered office at
Alderley Park, Cheshire. It is listed on AIM in London and trades
under the ticker symbol EVG.
For further information, please visit: www.evgen.com
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
NORFSWFAFEESESE
(END) Dow Jones Newswires
December 02, 2022 02:00 ET (07:00 GMT)
Evgen Pharma (LSE:EVG)
Gráfica de Acción Histórica
De Mar 2024 a Abr 2024
Evgen Pharma (LSE:EVG)
Gráfica de Acción Histórica
De Abr 2023 a Abr 2024